ING Group’s AstraZeneca AZN Stock Holding History

ING Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,975	Closed	-$363K	–	514
2025 Q4	$363K	Buy	1,975 +365	+23%	+$64K	﹤0.01%	526
2025 Q3	$247K	Sell	1,610 -5,096	-76%	-$771K	﹤0.01%	501
2025 Q2	$937K	Buy	6,706 +4,186	+166%	+$587K	0.01%	406
2025 Q1	$370K	Buy	+2,520	New	+$365K	﹤0.01%	455
2023 Q4	–	Sell	-35,387	Closed	-$4.79M	–	553
2023 Q3	$4.79M	Buy	35,387 +33,615	+1,897%	+$4.59M	0.04%	278
2023 Q2	$254K	Sell	1,772 -428	-19%	-$63K	﹤0.01%	474
2023 Q1	$305K	Sell	2,200 -25,401	-92%	-$3.42M	﹤0.01%	497
2022 Q4	$3.74M	Buy	27,601 +4,719	+21%	+$592K	0.04%	272
2022 Q3	$2.51M	Buy	22,882 +6,027	+36%	+$765K	0.04%	251
2022 Q2	$2.23M	Buy	16,855 +9,411	+126%	+$1.23M	0.03%	380
2022 Q1	$988K	Buy	+7,444	New	+$893K	0.01%	459
2014 Q2	–	Sell	-10,000	Closed	-$649K	–	643
2014 Q1	$649K	Buy	+10,000	New	+$646K	﹤0.01%	601
2013 Q4	–	Sell	-155,742	Closed	-$8.09M	–	690
2013 Q3	$8.09M	Sell	155,742 -745,179	-83%	-$37.4M	0.04%	327
2013 Q2	$42.6M	Buy	+900,921	New	+$45.9M	0.23%	117

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

ING Group's AZN Position: Q1 2026 in Review

ING Group sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,975 shares — an estimated $363K sold.

ING Group first reported a position in AZN in Q2 2013 and held it in 14 quarters. The position peaked at $42.6M in Q2 2013. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

ING Group reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
ING Group sold 1,975 AstraZeneca shares in Q1 2026, an estimated $363K.
ING Group first reported a position in AstraZeneca in Q2 2013 and held it in 14 quarters.
ING Group's AstraZeneca position peaked at $42.6M in Q2 2013.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on ING Group's 13F filing for Q1 2026, filed 11 May 2026.